F10 and Thromboembolism: A Chinese multicenter study (NCT03161496) showed in 257 patients with non-valvular AF in therapy with Rivaroxaban the association of the single nucleotide polymorphism USD3 rs76292544 with 12-month bleeding events and of NCMAP rs4553122, PRF1 rs885821, PRKAG2 rs12703159, rs13224758, and POU2F3 rs2298579 with peak anti-FXa level but also the preventive efficacy of Rivaroxaban pharmacokinetic–pharmacodynamic over thromboembolism in a subset of 136 patients vs. 26 healthy controls [112].